{"data":{"id":625,"lang":"en","title":"French Pharma Giant Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion in Childhood Cancer Drug Deal","summary":"Servier will pay $21.50 per share, a 68% premium, to acquire Day One and its pediatric brain cancer drug Ojemda, which generated $155 million in its first full year.","category":"business","category_label":"Business","published_at":"2026-03-07T07:02:04Z","updated_at":"2026-03-07T07:02:04Z","url":"https://techtools.cz/tools/news/article/625-french-pharma-giant-servier-to-acquire-day-one-biopharmaceuticals-for-2-5","api_url":"https://techtools.cz/news-api/v1/articles/625?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/625.md?lang=en","image_url":"https://medcitynews.com/wp-content/uploads/sites/7/2018/05/GettyImages-635475308.jpg","word_count":154,"reading_time_minutes":1,"sources":[{"url":"https://www.statnews.com/2026/03/06/servier-dayone-pediatric-cancer/","domain":"statnews.com"},{"url":"https://medcitynews.com/2026/03/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn/","domain":"medcitynews.com"},{"url":"https://www.biopharmadive.com/news/day-one-servier-acquisition-deal-cancer-drug-research-biotech/814065/","domain":"biopharmadive.com"}],"translation":{"lang":"cs","id":633,"title":"Francouzský farmaceutický gigant Servier kupuje Day One Biopharmaceuticals za 2,5 miliardy dolarů","url":"https://techtools.cz/tools/news/clanek/633-francouzsky-farmaceuticky-gigant-servier-kupuje-day-one-biopharmaceuticals-za-2","api_url":"https://techtools.cz/news-api/v1/articles/633?lang=cs"},"content":"French pharmaceutical company Servier announced a $2.5 billion deal to acquire Day One Biopharmaceuticals, the maker of Ojemda — the first targeted therapy approved for pediatric low-grade glioma, the most common form of childhood brain cancer. Servier is offering $21.50 per share in cash, representing a 68% premium over Day One's closing price.\n\nOjemda generated $155.4 million in sales during 2025, its first full year on the U.S. market. A Phase 3 trial is underway to expand its use as a first-line treatment, and a European regulatory decision is expected later in 2026. The deal also brings Day One's pipeline, including DAY301, an antibody-drug conjugate targeting PTK7 currently in Phase 1 testing.\n\nServier CEO David Lee said the company remains \"very open to areas that are really novel, innovative.\" Day One CEO Jeremy Bender noted that Servier's global footprint will help Ojemda \"reach many more patients.\" The transaction is expected to close in Q2 2026."}}